XENETIC BIOSCIENCES (XBIO) to Acquire Swiss Santersus in Reverse Merger
Xenetic will buy all shares of Santersus AG in a stock-for-stock deal, rename itself Santersus Bio and plans a reverse stock split.
Xenetic Biosciences (XBIO) has signed a share exchange agreement to acquire all issued and outstanding shares of Santersus AG, a Swiss company, in exchange for newly issued shares of Xenetic common stock. The agreement is dated September 14, 2026 and was disclosed in an 8-K filing that flags both a material definitive agreement and an unregistered issuance of equity securities.
